How'd you fix Eargo's revenue issues in 2026?

The outcome you should expect

The realistic outcome for Eargo in 2026 is not a dramatic reversal but a steady, multi-quarter stabilization. A company coming out of a DOJ settlement over insurance billing practices does not regain institutional and consumer trust in one campaign cycle — it regains it the way any regulated health brand does: through consistent, boring, well-documented behavior over several quarters. The realistic target is a return to gross revenue growth in the low double digits year-over-year, driven primarily by direct-to-consumer volume rather than a quick B2B rebound, since insurers and payers are the slowest-moving trust constituency Eargo has.

What actually changes first is unit economics, not headline revenue. Because OTC hearing aids under the FDA's 2022 rule opened the category to lower price points and non-audiologist retail channels, Eargo's near-term win is capturing customers who were previously priced out of prescription-channel devices but distrust the cheapest commodity options. That segment — buyers who want more than a $300 infomercial device but can't or won't pay $4,000 for full audiology-backed hardware — is where a repositioned Eargo can plausibly take share from Costco's Kirkland Signature line, MDHearingAid, and Audicus without having to out-market Costco's retail trust or out-price the rock-bottom OTC players.

The honest expectation is also that legacy revenue lines shrink before new ones offset them. Any SKU rationalization, subscription pilot, or B2B renegotiation creates a temporary revenue trough as old contracts wind down and new ones ramp. Leadership and investors should expect quarter-over-quarter volatility in 2026 even if the underlying trend line is recovering, because the company is simultaneously changing its pricing architecture, its channel mix, and its compliance posture — three variables moving at once always produces noisier quarterly numbers than a single-variable fix would.

What drives that outcome

Three forces determine whether Eargo's revenue actually recovers or merely stabilizes at a lower base: how fast the OTC narrative replaces the fraud narrative in the minds of both consumers and channel partners, how disciplined the RevOps foundation is underneath the sales and marketing motion, and how quickly customer acquisition cost comes down without sacrificing retention. These three forces interact — a good narrative without RevOps discipline just produces leads that leak out of a broken funnel, and clean RevOps without a rebuilt trust story still faces a CAC ceiling because paid channels alone can't overcome reputational drag.

The RevOps piece is easy to underweight but is arguably the highest-leverage lever, because it is the only one Eargo fully controls. A DTC hearing aid company selling through both direct channels and insurance-adjacent B2B relationships almost always ends up running a patchwork of CRM, marketing automation, and order management tools that don't talk to each other cleanly. Every handoff gap between "lead captured," "hearing test scheduled," "device shipped," and "insurance claim resolved" is a place revenue quietly disappears — not through fraud, but through ordinary operational friction: a lead that never gets a follow-up call, a claim that gets denied and never resubmitted, a customer whose warranty status nobody tracks. Fixing that is unglamorous but it is the difference between a marketing-driven bounce and a durable recovery.

Benchmarks and realistic ranges

Direct-to-consumer hearing aid economics give a useful frame for what "realistic" looks like for Eargo in 2026, even without company-specific guidance. Consumer hearing aid pricing in the OTC-to-prescription spectrum generally spans from roughly $300–$600 for the most basic OTC devices, through the $900–$1,500 range typical of retailer-backed options like Costco's in-house line, up to $2,000–$4,000+ for premium DTC and full audiology-supported devices. A company trying to serve more than one of those tiers needs genuinely distinct SKUs and marketing, not just discounting one product — a single device marked down doesn't create the segmentation a real price ladder does.

On the acquisition side, DTC health-tech categories with a consultative, higher-price sale commonly see customer acquisition costs anywhere from several hundred dollars up to low four figures, heavily dependent on paid social and search saturation in the category. Categories that lean on creator and community-driven content, rather than pure paid media, generally see CAC compress over time as organic reach and referral activity increase — but that compression takes sustained months of content investment, not a single campaign quarter. Return rates in hearing aids are a meaningful benchmark too: first-90-day returns in the 10–15% range are typical across the category when onboarding is weak, and well-run onboarding programs in comparable consumer medical device categories can bring that down meaningfully, though the exact percentage varies by brand and device type.

On the RevOps side, a common industry rule of thumb is that fragmented systems and unmanaged handoffs between marketing, sales, and fulfillment cost mid-market DTC and B2B2C companies somewhere in the high single digits to low double digits as a percentage of potential revenue — lost not to bad product-market fit but to leads and claims that fall through operational cracks. That range is a helpful sanity check for how much upside a RevOps cleanup alone can realistically unlock, independent of any pricing or channel change.

Risks, edge cases, and failure modes

The biggest risk is sequencing the trust-rebuild backwards. If Eargo leads with aggressive price cuts or heavy discount-driven promotion before the FDA OTC repositioning has landed with consumers and channel partners, it reinforces the impression of a company that needs to buy back attention rather than one that has genuinely changed. Price moves should follow the narrative reset, not substitute for it.

A second failure mode is repeating the underlying incentive structure that produced the original problem. If new B2B or insurance-facing partnerships are compensated in a way that rewards volume of claims submitted rather than verified patient outcomes, the company risks recreating the same misaligned incentives that led to the DOJ settlement in the first place — just with a different name on the program. Any outcome-based or risk-share payment structure needs genuinely independent verification of adherence or outcomes, not self-reported data from the same sales organization being compensated on it.

A third risk sits in retail and channel partnerships: a white-label or wholesale arrangement with a big-box retailer can rebuild trust by association, but it also compresses margin significantly and creates channel conflict with Eargo's own DTC pricing if not carefully firewalled. Retailers negotiating from a position of strength — knowing Eargo needs the trust halo more than the retailer needs Eargo's product — will extract terms that can make the arrangement revenue-positive but margin-negative for years.

Finally, there's a data risk specific to the RevOps rebuild: merging DTC and B2B/insurance customer records into a single source of truth, while necessary for forecasting and retention work, raises health data handling obligations. Any unified customer profile that includes hearing test results, device usage, or insurance claim status needs to be built with the same compliance rigor that got Eargo into trouble in the first place — treating this as a pure sales-and-marketing data project without compliance and legal sign-off is how a well-intentioned fix creates the next enforcement issue.

A practical rollout plan

The sequencing that minimizes risk starts with the parts of the fix Eargo fully controls before it depends on external trust — because internal RevOps and product changes can be executed and measured immediately, while narrative and channel trust take longer to move regardless of effort.

In practice, phase one — the RevOps and data cleanup — should run for roughly one to two quarters before the company leans hard into new customer acquisition spend, because pouring acquisition budget into a leaky funnel just amplifies the leak. Phase two, SKU rationalization, can run in parallel since it's largely a merchandising and manufacturing decision independent of the data work. The narrative and creator-partnership phase should only scale once the first two are stable, because a surge of new leads into a still-broken operational pipeline produces exactly the kind of customer experience failures that reinforce distrust. Retail piloting and B2B rebuilding come last deliberately: both require Eargo to demonstrate operational and compliance discipline externally before a retailer or an insurer will extend the kind of partnership terms that make those channels revenue-positive rather than margin-eroding.

Each phase needs its own success metric before the company moves to the next: data unification is done when lead-to-fulfillment time and claim-denial rates are tracked in one dashboard, not when the software migration is technically complete; the price ladder is working when each tier shows distinct customer profiles rather than pure cannibalization of the tier above it; and the narrative phase is working when unaided brand association shifts measurably away from the DOJ settlement in consumer research, not simply when campaign impressions hit a target.

Related questions

Why did Eargo's revenue issues start in the first place?

A DOJ settlement over insurance billing practices damaged trust with both consumers and payers, coinciding with a wave of cheaper OTC competitors entering the market after the 2022 FDA rule change, which compressed Eargo's pricing advantage at the same time.

Is the OTC hearing aid market big enough to rebuild a company like Eargo on?

Yes — the FDA's OTC rule substantially expanded the addressable market by removing the audiologist-visit requirement, but it also invited lower-cost competitors, so the opportunity is real only if Eargo differentiates rather than competing purely on price.

Should Eargo prioritize DTC or B2B insurance revenue first?

DTC, because it doesn't require rebuilding trust with a third-party payer first — insurers and channel partners typically move slower to re-engage than individual consumers responding to a repositioned brand story.

How long does a reputational recovery like this typically take?

Comparable consumer health brands recovering from regulatory settlements generally need multiple quarters to a few years of consistent, verifiable behavior before institutional trust (payers, retail partners) meaningfully returns, even when consumer sentiment recovers faster.

FAQ

What was the core cause of Eargo's revenue issues? A DOJ settlement tied to insurance billing practices damaged the company's standing with payers and consumers, and that reputational hit landed at the same time OTC competitors were entering the market at lower price points, squeezing Eargo from both directions.

Can Eargo compete with Costco on price alone? No — Costco's Kirkland Signature line has retail trust and scale Eargo cannot match on price, so the more durable strategy is differentiating on service, technology, or a distinct price tier rather than a direct price war.

What role does RevOps play in fixing Eargo's revenue issues? RevOps closes the operational gaps — fragmented CRM data, disconnected marketing and fulfillment systems, unmanaged insurance claim workflows — where revenue is lost to friction rather than to competition, and it's a fix Eargo can execute without depending on external trust recovery.

Is a subscription model realistic for a hearing aid company? It's plausible given how infrequently consumers replace hearing aids, but it depends on proving retention economics with a small pilot group first, since converting a one-time purchase into a recurring plan changes cash flow timing and requires strong ongoing service delivery.

How risky is a retail partnership like Costco or Best Buy for Eargo? It can rebuild trust quickly through association but usually compresses margin significantly and risks channel conflict with DTC pricing, so it needs careful terms and a clear firewall between retail and direct pricing.

Should Eargo change how it compensates its sales team? Yes — moving away from pure volume-based incentives toward compensation tied to verified customer retention and outcomes reduces the risk of recreating the incentive misalignment that contributed to the original DOJ issues.

Sources

• https://www.fda.gov/medical-devices/hearing-aids/overview-hearing-aids
• https://www.justice.gov/opa/pr
• https://www.sec.gov/edgar/search/
• https://www.hearingtracker.com
• https://www.costco.com/kirkland-signature-hearing-aids.html
• https://www.consumerreports.org/health/hearing-aids/
• https://www.hearingreview.com
• https://www.statista.com/topics/hearing-aids/

Related on PULSE

• How'd you fix Illinois's NIL & athletic revenue issues in 2026?
• How'd you fix Aston Carter's revenue issues in 2026?
• How'd you fix CyberCoders's revenue issues in 2026?
• How'd you fix Creative Financial Staffing's revenue issues in 2026?
• How'd you fix LanceSoft's revenue issues in 2026?
• How'd you fix Goodwin Recruiting's revenue issues in 2026?